PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Global Head At Boehringer to Speak At CNS Partnering Meeting September 22-23 in San Francisco - Klaus D. Mendla, Head of Global Business Development and Licensing CNS at Boehringer Ingelheim, will give a featured presentation on “Sincerely, Yours – Partnering with Boehringer Ingelheim in the CNS Space” at the 4th CNS Partnering
Global Head At Boehringer to Speak At CNS Partnering Meeting September 22-23 in San Francisco

 

NewswireToday - /newswire/ - Monrovia, CA, United States, 2011/07/18 - Klaus D. Mendla, Head of Global Business Development and Licensing CNS at Boehringer Ingelheim, will give a featured presentation on “Sincerely, Yours – Partnering with Boehringer Ingelheim in the CNS Space” at the 4th CNS Partnering.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Partnering with Boehringer Ingelheim in the CNS Space” at the 4th CNS Partnering and Deal-making Conference to be held in San Francisco, CA on September 22-23, 2011 by GTC.

Klaus Mendla will outline Boehringer Ingelheim’s partnering strategy in the indication areas of chronic pain, neurodegenerative diseases (core indications: AD and Parkinson’s disease), and psychiatric disorders (core indications: schizophrenia and depression). Boehringer Ingelheim is interested in compounds with a novel mode of action and a sound scientific rationale for improved efficacy and/or safety/tolerability compared to current standards of care. In addition to the level of scientific and medical innovation, the overall attractiveness of a licensing candidate would clearly benefit from a combination with suitable biomarkers and predictive preclinical models. For each of the core indications for CNS Licensing, Klaus will also discuss Target Licensing Product Profiles (TLPP).

Highlights of Klaus Mendla’s presentation:

• Why does the CNS market represent an attractive investment opportunity for Pharma?
• What are the key unmet medical needs in the treatment of chronic pain, neurodegenerative diseases, and psychiatric disorders?
• What kind of partnering opportunities in the CNS space is Boehringer Ingelheim interested in?

Klaus Mendla is Head of Global Business Development and Licensing CNS at Boehringer Ingelheim. He leads the cross-functional CNS Advisory Team responsible for global licensing activities in the therapeutic area Central Nervous System Diseases (covering projects from preclinical leads to late-stage clinical and marketed products). Since joining Boehringer Ingelheim in 1985, he has held several positions in Research and Development within the corporation. Before joining Boehringer Ingelheim’s International Business Development and Licensing organization, Dr. Mendla was director of the company’s Neurodegeneration Research Group.
His current focus is on licensing projects in the area of neurodegenerative diseases (including Alzheimer’s and Parkinson’s disease), chronic pain, and psychiatric disorders.

The 4th CNS Partnering and Deal-making Conference gives global biotechnology and pharmaceutical companies in the CNS industry an opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, as well as explore potential collaborations, and learn about relevant CNS Disease issues and partnerships that will affect the industry.

This event also provides a unique venue for attendees to learn about CNS Diseases business trends, the CNS disease market, and novel technologies that shape the industry. The conference is part of the CNS Diseases World Summit, which consists of 3 tracks including the “5th Neurodegenerative Conditions Research and Development” and “Advances in Neuropsychiatric Treatment”.

The sessions for the conferences are:
• Plenary Keynote Session
• Investments and Partnerships in the CNS Space
• Addressing Regulatory and Financial Decisions for Investments and Startups
• Recent Advances in CNS Development
• Case Studies in the Clinical Space
• Strategic Direction in Neuroscience
• Current Trends and Recent Deals.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Global Head At Boehringer to Speak At CNS Partnering Meeting September 22-23 in San Francisco

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: GTCbio.com 
626-256-6405 infogtcbio[.]gtcbio.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  Triggr & Bloom





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)